CIK: 0001560009 · Show all filings
Period: Q4 2020 (← Previous) (Next →)
Filing Date: Feb 16, 2021
Total Value ($000): $962,968 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 3,040,462 | $465,525 | 48.3% | $40.26 | +193.6% | Common Shares | H17182108 |
| — | Inari Medical, Inc. | 2,298,217 | $200,611 | 20.8% | $87.29 | — | Common Stock | 45332Y109 |
| — | Aligos Therapeutics, Inc. | 3,292,339 | $91,033 | 9.5% | $27.65 | — | Common Stock | 01626L105 |
| — | Adverum Biotechnologies, Inc. | 5,003,892 | $54,242 | 5.6% | $9770.00 | — | Common Stock | 00773U108 |
| — | Flexion Therapeutics, Inc. | 3,842,578 | $44,343 | 4.6% | $10.41 | — | Common Stock | 33938J106 |
| OCUL | Ocular Therapeutix, Inc. | 1,465,384 | $30,333 | 3.1% | $20.09 | -26.1% | Common Stock | 67576A100 |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2,030,616 | $28,652 | 3.0% | $17.05 | -18.3% | Common Stock | 22663K107 |
| — | Akero Therapeutics, Inc. | 777,727 | $20,065 | 2.1% | $21200.00 | — | Common Stock | 00973Y108 |
| — | Gritstone Oncology, Inc. | 4,450,638 | $17,536 | 1.8% | $7767.86 | — | Common Stock | 39868T105 |
| — | Aprea Therapeutics, Inc. | 1,426,328 | $7,018 | 0.7% | $38780.00 | — | Common Stock | 03836J102 |
| — | CymaBay Therapeutics, Inc. | 543,753 | $3,121 | 0.3% | $9871.60 | — | Common Stock | 23257D103 |
| — | Clovis Oncology, Inc. | 101,855 | $489 | 0.1% | $56000.00 | — | Common Stock | 189464100 |